Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Tax Provisions (2021 - 2025)

Barinthus Biotherapeutics' Tax Provisions history spans 5 years, with the latest figure at -$57000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 2000.0% year-over-year to -$57000.0; the TTM value through Dec 2025 reached -$175000.0, down 297.73%, while the annual FY2025 figure was -$175000.0, 297.73% down from the prior year.
  • Tax Provisions reached -$57000.0 in Q4 2025 per BRNS's latest filing, up from -$71000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $32000.0 in Q4 2021 to a low of -$2.0 million in Q4 2022.
  • Average Tax Provisions over 5 years is -$389650.0, with a median of -$61000.0 recorded in 2021.
  • Peak YoY movement for Tax Provisions: plummeted 9528.57% in 2022, then soared 100.37% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $32000.0 in 2021, then plummeted by 6409.38% to -$2.0 million in 2022, then skyrocketed by 59.39% to -$820000.0 in 2023, then soared by 100.37% to $3000.0 in 2024, then tumbled by 2000.0% to -$57000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Tax Provisions are -$57000.0 (Q4 2025), -$71000.0 (Q3 2025), and -$25000.0 (Q2 2025).